AstraZeneca stated Thailand, which is manufacturing its vaccine domestically, can have acquired its agreed quota of 6 million doses inside this month, whereas export to different Southeast Asian international locations will begin in early July.
In a press release, AstraZeneca Thailand stated companion Siam Bioscience, owned by King Maha Vajiralongkorn, will produce 180 million doses this 12 months, simply over a 3rd for Thailand and two thirds for elsewhere in Southeast Asia.
It didn’t present particulars of the standing and quantity of the orders for different international locations. AstraZeneca and Siam Bioscience didn’t instantly reply to requests for remark.
Thailand’s mass vaccination drive depends closely on the AstraZeneca vaccine and it skilled preliminary manufacturing delays that additionally affected Malaysia, the Philippines and Taiwan.
Thailand has additionally used Sinovac Biotech’s vaccine, with 10.5 million doses acquired to date and 37 million on order.
Its well being ministry on Monday stated two doses of the Sinovac vaccine was proven to be 95% efficient in lowering situations of mortality and extreme signs, based mostly on its real-world knowledge research.
The research confirmed 71% to 91% efficacy in lowering an infection in opposition to the Alpha variant first recognized in Britain, which has been detected in 80% of Thailand’s instances since April.
The ministry warned, nonetheless, that infections with the Delta variant first recognized in India have elevated considerably previously week, up 30% within the outbreak epicentre Bangkok.